Pacira BioSciences’ (PCRX) Hold Rating Reiterated at Jefferies Financial Group

Pacira BioSciences (NASDAQ:PCRX)‘s stock had its “hold” rating restated by equities research analysts at Jefferies Financial Group in a research report issued on Thursday, Benzinga reports. They presently have a $36.00 target price on the stock. Jefferies Financial Group’s target price indicates a potential downside of 1.06% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Zacks Research cut shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research report on Monday. Needham & Company LLC reissued a “hold” rating on shares of Pacira BioSciences in a research note on Thursday. Royal Bank Of Canada upped their target price on Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 5th. Leerink Partners assumed coverage on Pacira BioSciences in a research note on Wednesday, September 9th. They set a “market perform” rating and a $28.00 target price for the company. Finally, Wall Street Zen upgraded Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 26th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and an average target price of $31.00.

Pacira BioSciences Trading Up 44.4%

Pacira BioSciences stock traded up $11.19 during mid-day trading on Thursday, hitting $36.38. 27,177,996 shares of the stock were exchanged, compared to its average volume of 800,578. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 103.96 and a beta of 0.25. Pacira BioSciences has a 12 month low of $18.80 and a 12 month high of $36.39. The company has a quick ratio of 3.94, a current ratio of 5.04 and a debt-to-equity ratio of 0.54. The firm’s fifty day simple moving average is $25.18 and its two-hundred day simple moving average is $24.41.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.08. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The company had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. During the same period in the prior year, the firm posted $0.74 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Analysts forecast that Pacira BioSciences will post 1.91 EPS for the current year.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $23.23, for a total value of $70,619.20. Following the completion of the sale, the insider directly owned 216,384 shares in the company, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pacira BioSciences

Institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its holdings in Pacira BioSciences by 5.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,060,597 shares of the company’s stock worth $46,572,000 after acquiring an additional 110,584 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Pacira BioSciences by 17.8% during the second quarter. Wellington Management Group LLP now owns 563,458 shares of the company’s stock valued at $14,295,000 after acquiring an additional 85,075 shares in the last quarter. Gagnon Securities LLC increased its holdings in shares of Pacira BioSciences by 11.5% during the fourth quarter. Gagnon Securities LLC now owns 501,211 shares of the company’s stock valued at $12,971,000 after acquiring an additional 51,494 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Pacira BioSciences during the second quarter worth approximately $7,532,000. Finally, Hillsdale Investment Management Inc. raised its position in shares of Pacira BioSciences by 7.5% during the first quarter. Hillsdale Investment Management Inc. now owns 331,300 shares of the company’s stock worth $7,487,000 after purchasing an additional 23,100 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

More Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris agreed to acquire Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction offers shareholders a defined cash exit and places the stock close to the proposed purchase price. The deal is expected to close by the end of 2026, subject to customary conditions. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: The acquisition gives Viatris control of Pacira’s marketed non-opioid pain medicines, Exparel and Zilretta. Viatris expects to use its international infrastructure and commercial capabilities to expand the products, while citing potential synergies with its fast-acting meloxicam opportunity. Viatris to Buy Pacira BioSciences for $1.65 Billion
• Neutral Sentiment: Needham reaffirmed its “hold” rating. Earlier, Truist raised its target to $31 and maintained a “buy” rating, but that target is below the proposed takeover price.
• Negative Sentiment: Ademi LLP and Halper Sadeh LLP announced investigations into whether the $36.50 offer fairly values Pacira, whether directors adequately protected shareholders, and whether insiders received favorable benefits. These announcements could increase deal-related uncertainty, although shareholder law-firm investigations are common after public takeovers. PCRX Shareholder Alert: Ademi LLP Investigation
• Negative Sentiment: Unusual options activity indicated bearish positioning in PCRX, while Zacks recently downgraded the stock to “strong sell.” These signals are secondary to the acquisition announcement but highlight potential concerns about valuation or deal risk.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.